Právní předpis byl sestaven k datu 01.01.2025.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
XXXXXXXX XXXXX
xx dne 11. prosince 2024,
kterým xx xxxx nařízení xxxxx x. 463/2013 Xx., o xxxxxxxxx xxxxxxxxxx xxxxx, xx xxxxx pozdějších předpisů
Vláda xxxxxxxx xxxxx §44c xxxx. 1 x 2 xxxxxx x. 167/1998 Xx., x xxxxxxxxxx látkách x x xxxxx některých xxxxxxx zákonů, xx xxxxx xxxxxx x. 273/2013 Xx. x xxxxxx x. 366/2021 Xx.:
Čl. X
Xxxxxxxx xxxxx x. 463/2013 Sb., x xxxxxxxxx xxxxxxxxxx xxxxx, xx xxxxx xxxxxxxx vlády č. 243/2015 Xx., nařízení xxxxx č. 46/2017 Xx., xxxxxxxx xxxxx x. 30/2018 Sb., xxxxxxxx xxxxx x. 242/2018 Xx., xxxxxxxx xxxxx x. 184/2021 Xx., xxxxxxxx xxxxx x. 159/2022 Xx., xxxxxxxx xxxxx x. 228/2023 Sb., xxxxxxxx xxxxx x. 52/2024 Xx. a xxxxxxxx xxxxx č. 176/2024 Xx., xx xxxx xxxxx:
1. X tabulce xxxxxxx č. 1 xx xxx xxxxx, xx xxxxxx je xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx jazyce“ xxxxxxx xxxxx „Thebakon“, xxxxxx xxxx xxxxx, xx xxxxxx xx xx xxxxxxx s xxxxxx „Xxxxxxxxxxx nechráněný název (XXX) v xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxx“, xx sloupci x xxxxxx „Xxxxxxxx xxxxx podle XXXXX“ xx xxxxxxx xxxxx „xxxxxx 4-(X-(2-xxxxxxxxxxxxx)xxxxxx)-1-(2-xxxxxxx-2-xxxxxxx)xxxxxxxxx-4-xxxxxxxxxx“ x xx xxxxxxx x xxxxxx „Xxxxxxxx“ xxxx xxxxxxx xxxxx „X-3080, Xxxxxxx“.
2. Příloha č. 3 xxx:
„Xxxxxxx x. 3
Xxxxxx x. 3 xxxxxxxx látek
|
Mezinárodní xxxxxxxxxx xxxxx (XXX) v českém xxxxxx / xxxxxx xxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxxx další xxxxxx xxxxx |
Xxxxxxxx xxxxx xxxxx XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)-xxxxxxxx |
XXX 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- cinnamylpiperazine; |
1-[4-(3-fenylprop-2-en-1-yl)piperazin-1-yl]butan-1-on |
|
|
AP-238 |
1-[2,6-dimethyl-4-(3-fenylprop-2-enyl)piperazin-1-yl]propan-1-on |
||
|
Benzodioxolfentanyl |
BZD-F; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx FuF |
N-(1-benzylpiperidin-4-yl)-N-fenylfuran-2-karboxamid |
|
|
Bromadolin |
U 4793x; U 47931X |
4-xxxx-X-(2-(xxxxxxxxxxxxx) xxxxxxxxxx) benzamid |
|
|
Brorfin |
Brorphine |
3-{1-[1-(4-bromfenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-on |
|
|
Butonitazen |
2-[(4-butoxyfenyl)methyl]-N,N-diethyl-5-nitro-lA-benzimidazol-1-ethanamin |
||
|
4-Chlorisobutyrfentanyl |
4-Cl-iBF |
N-(4-chlorfenyl)-2-methyl-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
|
|
Cyklopentylfentanyl |
cyclopentyl-F; CP-F |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]cyklopentankarboxamid |
|
|
Cyklopropylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]cyklopropankarboxamid |
||
|
Desmethylmoramid |
R530 |
4-(4-morfolinyl)-2,2-difenyl-1-(1-pyrrolidinyl)-1-butanon |
|
|
Desomorfin |
4,5α-epoxy-17-methylmorfinan-3-ol |
||
|
Despropionyl-2-fluor xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx xxxxxxxx |
X-(4-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxx |
4,4-xxxxxxx-6-(xxxxxxxxxx-1-xx)xxxxxx-3-xx |
||
|
Xxxxxx |
xxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]-X,X-xxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
2-{2-[(2,3-xxxxxxx-1-xxxxxxxxxx-5-xx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}-X,X- diethylethan-1-amin |
||
|
Etometazen |
5-methyl xxxxxxxxxxxxx; 5-xxxxxx desnitroetonitazen |
2-[(4-ethoxyfenyl)methyl]-N,N-diethyl-5-methyl-1H-benzimidazol-1-ethanamin |
|
|
Etonitazepipne |
N-piperidinyletonitazen |
2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1N-benzo[d]imidazol |
|
|
Etonitazepin |
2-[(4-ethoxyfenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzoimidazol |
||
|
Etorfin |
(5R,6R,7R,14R)-4,5-epoxy-7-[(2R)-2-hydroxypentan-2-yl]-6-methoxy-17-methyl-6,14-ethenomorfinan-3-ol |
||
|
Fentanyl xxxxxxxxx xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Xxxxxxxxxxxxxxxxxxxxx |
β'-xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-x]-3-xxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxx |
|
Xxxxxxxxxx |
X,X-xxxxxxx-2-{2-[(4-xxxxxxxxxx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}xxxxxxxxx |
||
|
2’-Xxxxx-2-xxxxx-3-xxxxxxxxxxxxxx |
X-(1-(2-xxxxxxxxxxxxx)-3-xxxxxxxxxxxxxxx-4-xx)-X-(2-xxxxxxxxxx)xxxxxxxxxxx |
||
|
4-Xxxxx-xxxxxxxxxxxxx |
4X-XX |
X-(4-xxxxxxxxxx)-X-[(1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx)]xxxxxxxxx |
|
|
4-Xxxxx-xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxxxx- fentanyl |
N-(4-fluorfenyl)-N-(1-benzylpiperidin-4-yl)-cyklopropankarboxamid |
|
|
2-Fluorfentanyl |
Ortofluorfentanyl |
N-(2-fluorfenyl)-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
2-FF, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, x-XX |
|
4-Xxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxx; 4F-furanylfentanyl |
N-(4-fluorfenyl)-N-(1-fenethylpiperidin-4-yl)furan-2-karboxamid |
|
|
4-Fluorisobutyrfentanyl |
4F-1BF |
N-(4-fluorfenyl)-2-methyl-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
|
|
3-FluormethoxyacetyIfentanyl |
ortho-fluormethoxyacetyl- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx UF-17 |
N-[2-(dimethylamino)cyklohexyl]-N-fenyl-furan-2-karboxamid |
||
|
Furanylfentanyl |
FU-F; 2-xxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxx-2-xxxxxxxxxx |
|
|
(xxx)Xxxxxxx-X-xxxxxxxx X-xxxxxx xxxxxx |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-(4-xxxxxxxxxx)xxxxxxxxx |
||
|
Xxxxxx |
(5X,6X)-4,5-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6-xxxx-xxxxxxxx |
||
|
4-xxxxxxxxxxxxxxxxxxxx |
4-XX-XX; x-xxxxxxxxxxxxxx xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx amin |
||
|
Karbonyl-bromadol |
(4-bromfenyl)-(1-(dimethylamino)-4-hydroxy-4-fenethylcyklohexyl)methanon |
||
|
Ketobemidon |
1-[4-(3-hydroxy xxxxx)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X xxxxxxxx xxxxxx xxx xxxxxxx xxxxxxx xxxxxxx v xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; MDU-47; MDU-47700 |
N-(2-(dimethylamino)cyklohexyl)-N-methylbenzo[d][1,3]dioxol-5-karboxamid |
|
|
α-Methylfentanyl xxxxxxxxx xxxxxx |
XX; X-X |
2-xxxxxx-X-xxxxx-X-[1-(1-xxxxxxxxxxx-2-xx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
3 -XxxxxXxxxxxxxXxxxxxxxx |
β'-xxxxxXxxxxxxxXxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-3-xxxxxxxxx-2-xxxxxx |
|
|
Xxxxxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]-5-xxxxxxxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]-X-xxxxx-xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-2-[2-[(4-xxxxxxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
X-xxxxxx X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-xxxxxxxxxxx-1-xxxxxxxxxxxxx-3-xx-1-xxxxxxxxxx |
||
|
X-XXXX; xxxxxxxxxxxxxxxxxxxxxxxx |
3-(4-xxxxxx-1-xxxxxxxxxxxxxxx-4-xx)xxxxx xxxxxx |
||
|
XXxxxxxxxx |
X-3217 |
X-(2-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxx, XXX, 127C49 |
1-(4,4-di(thiofen-2-yl)but-3-en-2-yl)piperidin |
|
|
Protonitazen |
N,N-diethyl-5-nitro-2-[(4-propoxyfenyl)methyl]-1-H-benzimidazol-1-ethanamin |
||
|
Protonitazepin |
5-nitro-2-[(4-propoxyphenyl)methyl]-1-(2-pyrrolidin-1-ylethyl)benzimidazole |
||
|
Pryskyřice z konopí |
|||
|
Tetrahydrofuranfentanyl |
THF-F |
N-(1-fenylethylpiperidin-4-yl)-N-fenyltetrahydrofuran-2-karboxamid |
|
|
Tetramethylcyklopropanfentanyl |
TMCP-fentanyl; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxx |
2-xxxxxxxxxxx xxxxxxxx |
X-(1-xxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
4-(Xxxxxxxxxxxxxx) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] benzenacetamid |
||
|
U-51754 |
2-(3,4-dichlorfenyl)-N-[2-(dimethylamino)cyklohexyl]-N-methylacetamid |
||
|
ValeryIfentanyl |
TCE, VF |
A-fenyl-N-[1-(2-fenylethyl)-4-piperidyl]pentanamid; xxxxxxxx xxxxxxxxxx analog |
Včetně xxxx omamných xxxxx xxxxxxxxx x xxxx xxxxxxx xx xxxxx xxxxxxxxx, kdy tyto xxxx xxxxx xxxxxxxxx.“.
3. X tabulce přílohy x. 6 se xxx xxxxx, xx xxxxxx xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx nechráněný název (XXX) x xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxxx“, vkládá xxxx xxxxx, xx kterém xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx název (XXX) x xxxxxx jazyce“ xxxxxxx xxxxx „Xxxxxxxxxxxxxxxx“, xx sloupci s xxxxxx „Další xxxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxx obecný xxxxx“ xx xxxxxx text „XXX“, xx sloupci x názvem „Xxxxxxxx xxxxx podle IUPAC“ xx xxxxxxx xxxxx „xxxxxx-2-xx“ a ve xxxxxxx x xxxxxx „Xxxxxxxx“ je xxxxxxx xxxxx „xxxxx-xxxxxxxxxxxxx“.
Čl. XX
Xxxxxxxxx xxxxxxx
Xxxx xxxxxxxx xxxx oznámeno x souladu se xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) 2015/1535 ze dne 9. xxxx 2015 x postupu xxx xxxxxxxxxxx xxxxxxxxx x xxxxxxx technických xxxxxxxx x xxxxxxxx xxx xxxxxx xxxxxxxxxx společnosti.
Čl. XXX
Xxxxxxxx
Xxxx nařízení xxxxxx xxxxxxxxx xxxx 1. xxxxx 2025, x výjimkou xxxxxxxxxx čl. I xxxx 3, xxxxx xxxxxx xxxxxxxxx xxxx 1. dubna 2025.
&xxxx;
Xxxxxxxx xxxxx:
xxxx. XxXx. Xxxxx, Ph.D., XX.X., x. r.
Místopředseda xxxxx x xxxxxxx xxxxxxxxxxxxx:
xxxx. XXXx. Xxxxx, CSc., XXX, XXXX, x. x.
Informace
Právní xxxxxxx č. 419/2024 Xx. xxxxx xxxxxxxxx xxxx 1.1.2025, x výjimkou xxxxxxxxxx čl. I xxxx 3, xxxxx nabývá účinnosti 1.4.2025.
Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, pokud xx xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.